PET-CT for Intraductal Papillary Mucinous Neoplasm (IPMN)
Duct involved intraductal papillary mucinous neoplasm is associated with a 35-70%
(particularly involving the main duct) incidence of malignancy. Current guidelines recommend
pancreatic resection for fit patients with main or branch duct involved IPMN. Pancreatic
resection can be associated with morbidity and mortality. Reliable tests or biomarkers
accurately differentiating non-malignant from malignant duct involved IPMN are non-existent.
Test or biomarkers differentiating duct involved from duct uninvolved IPMN are also
inaccurate. Patients with suspected duct IPMN with symptoms have a higher chance of
associated malignancy. These findings are not specific for malignant IPMN so, if relied on,
they would results in missed malignancies as well as potentially unnecessary operations in a
significant percentage of patients. PET scanning has been studied retrospectively and
purported to be a highly reliable indicator og high grade dysplasia and/or invasive cancer
in patients with IPMN. Thus, PET could represent a future standard of care by some
authorities in the work-up of patients with IPMN. This proposal seeks to prove the
hypothesis that pancreas PET-CT can differentiate duct involved IPMN with malignancy from
duct involved IPMN without malignancy.
Observational Model: Case-Only, Time Perspective: Prospective
Pancreas PET-CT can differentiate duct involved IPMN with malignancy from duct involved IPMN without malignancy.
Christian M Schmidt, MD
United States: Institutional Review Board
|Indiana University Medical Center||Indianapolis, Indiana 46202|